Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 41
Maintaining global insulin leadership by sustaining modern
insulin market share
Novo Nordisk global volume market share across insulin classes
tMU
Human insulin¹
tMU
Modern insulin³
class volume
tMU
Novo Nordisk class MS (%)
Total insulin
500
100% 500
100% 500
100%
Market value²:
Market value²:
DKK 24 billion
DKK 212 billion
Market value²:
DKK 236 billion
400
80%
400
80% 400
80%
300
60%
300
- 60%
300
60%
200
40%
200
- 40%
200
100
20%
100
- 20%
100
0
0%
0
0%
Aug
Aug
Aug
Aug
2011
2016
2011
2016
-
40%
20%
0%
Aug
2011
Aug
2016
1 Includes animal insulin. 2 Annual value of total insulin class. 3 Includes new generation insulin
Note: Data is sensitive to changes in IMS data collection and reporting methodology
Source: IMS, Monthly MAT August, 2016 value and volume figures
changing
diabetes®
novo nordiskView entire presentation